SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
Checkpoint blockade has demonstrated promising antitumor responses in approximately 10-40% of patients. However, the majority of patients do not make a productive immune response to their tumors and do not respond to checkpoint blockade. These patients may benefit from an effective vaccine that stim...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Taylor & Francis
2016
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/49788/ |
| _version_ | 1848798078266507264 |
|---|---|
| author | Xue, Wei Metheringham, Rachael L. Brentville, Victoria A. Gunn, Barbara Symonds, Peter Yagita, Hideo Ramage, Judith M. Durrant, Lindy |
| author_facet | Xue, Wei Metheringham, Rachael L. Brentville, Victoria A. Gunn, Barbara Symonds, Peter Yagita, Hideo Ramage, Judith M. Durrant, Lindy |
| author_sort | Xue, Wei |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Checkpoint blockade has demonstrated promising antitumor responses in approximately 10-40% of patients. However, the majority of patients do not make a productive immune response to their tumors and do not respond to checkpoint blockade. These patients may benefit from an effective vaccine that stimulates high-avidity T cell responses in combination with checkpoint blockade. We have previously shown that incorporating TRP-2 and gp100 epitopes into the CDR regions of a human IgG1 DNA (ImmunoBody®: IB) results in significant tumor regression both in animal models and patients. This vaccination strategy is superior to others as it targets antigen to antigen-presenting cells and stimulates high-avidity T cell responses. To broaden the application of this vaccination strategy, 16 NY-ESO-1 epitopes, covering over 80% of HLA phenotypes, were incorporated into the IB (SCIB2). They produced higher frequency and avidity T cell responses than peptide vaccination. These T cells were of sufficient avidity to kill NY-ESO-1-expressing tumor cells, and in vivo controlled the growth of established B16-NY-ESO-1 tumors, resulting in long-term survival (35%). When SCIB2 was given in combination with Treg depletion, CTLA-4 blockade or PD-1 blockade, long-term survival from established tumors was significantly enhanced to 56, 67 and 100%, respectively. Translating these responses into the clinic by using a combination of SCIB2 vaccination and checkpoint blockade can only further improve clinical responses. |
| first_indexed | 2025-11-14T20:14:03Z |
| format | Article |
| id | nottingham-49788 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T20:14:03Z |
| publishDate | 2016 |
| publisher | Taylor & Francis |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-497882020-05-04T17:56:37Z https://eprints.nottingham.ac.uk/49788/ SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade Xue, Wei Metheringham, Rachael L. Brentville, Victoria A. Gunn, Barbara Symonds, Peter Yagita, Hideo Ramage, Judith M. Durrant, Lindy Checkpoint blockade has demonstrated promising antitumor responses in approximately 10-40% of patients. However, the majority of patients do not make a productive immune response to their tumors and do not respond to checkpoint blockade. These patients may benefit from an effective vaccine that stimulates high-avidity T cell responses in combination with checkpoint blockade. We have previously shown that incorporating TRP-2 and gp100 epitopes into the CDR regions of a human IgG1 DNA (ImmunoBody®: IB) results in significant tumor regression both in animal models and patients. This vaccination strategy is superior to others as it targets antigen to antigen-presenting cells and stimulates high-avidity T cell responses. To broaden the application of this vaccination strategy, 16 NY-ESO-1 epitopes, covering over 80% of HLA phenotypes, were incorporated into the IB (SCIB2). They produced higher frequency and avidity T cell responses than peptide vaccination. These T cells were of sufficient avidity to kill NY-ESO-1-expressing tumor cells, and in vivo controlled the growth of established B16-NY-ESO-1 tumors, resulting in long-term survival (35%). When SCIB2 was given in combination with Treg depletion, CTLA-4 blockade or PD-1 blockade, long-term survival from established tumors was significantly enhanced to 56, 67 and 100%, respectively. Translating these responses into the clinic by using a combination of SCIB2 vaccination and checkpoint blockade can only further improve clinical responses. Taylor & Francis 2016-06-15 Article PeerReviewed Xue, Wei, Metheringham, Rachael L., Brentville, Victoria A., Gunn, Barbara, Symonds, Peter, Yagita, Hideo, Ramage, Judith M. and Durrant, Lindy (2016) SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. Oncoimmunology, 5 (6). e1169353/1-e1169353/13. ISSN 2162-402X Cancer immunotherapy; CD4C T cells; CD8C T cells; targeting antigen-presenting cells; NY-ESO-1 https://www.ncbi.nlm.nih.gov/pubmed/27471648 doi:10.1080/2162402X.2016.1169353 doi:10.1080/2162402X.2016.1169353 |
| spellingShingle | Cancer immunotherapy; CD4C T cells; CD8C T cells; targeting antigen-presenting cells; NY-ESO-1 Xue, Wei Metheringham, Rachael L. Brentville, Victoria A. Gunn, Barbara Symonds, Peter Yagita, Hideo Ramage, Judith M. Durrant, Lindy SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade |
| title | SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade |
| title_full | SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade |
| title_fullStr | SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade |
| title_full_unstemmed | SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade |
| title_short | SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade |
| title_sort | scib2, an antibody dna vaccine encoding ny-eso-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade |
| topic | Cancer immunotherapy; CD4C T cells; CD8C T cells; targeting antigen-presenting cells; NY-ESO-1 |
| url | https://eprints.nottingham.ac.uk/49788/ https://eprints.nottingham.ac.uk/49788/ https://eprints.nottingham.ac.uk/49788/ |